On February 13, 2014, Sun Pharmaceutical Industries Ltd. reported financials for third quarter of 2013. The highlights of Q3 FY14 consolidated financials are as follows –

1) Net sales / Income from operations at Rs. 4287 crores, a growth of 50% over same quarter last year.
2) Branded generic sales in India at Rs. 947 crores, up by 20% over Q3 last year.
3) US finished dosage sales at US$ 434 million grew by 57% (in US$ terms) over Q3 last year.
4) International formulation sales outside US at US$ 84 million grew by 16% (in US$ terms) over same quarter last year.
5) Overall international revenues accounted for more than 75% of total revenues for the quarter.
6) EBITDA at Rs. 1975 crores grew by 57%; resulting EBITDA margin of 46%, compared to 44% for Q3 last year.
7) Net profit at Rs. 1531 crores compared to Rs. 881 crores for Q3 last year, up 74% over Q3 last year; resulting margin of 36%.

Share :